Icosabutate is an investigational drug.
There have been 5 clinical trials for Icosabutate.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 17th 2019.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Dyslipidemias. The leading clinical trial sponsors are Pronova BioPharma, NorthSea Therapeutics B.V., and [disabled in preview].
There are five US patents protecting this investigational drug and one hundred and five international patents.